Heron Therapeutics (HRTX) Receives Buy Rating from Oppenheimer

Oppenheimer restated their buy rating on shares of Heron Therapeutics (NASDAQ:HRTX) in a report released on Friday, November 10th. The brokerage currently has a $27.00 price objective on the biotechnology company’s stock. Oppenheimer also issued estimates for Heron Therapeutics’ FY2020 earnings at $1.45 EPS and FY2021 earnings at $3.29 EPS.

A number of other brokerages also recently weighed in on HRTX. Zacks Investment Research upgraded Heron Therapeutics from a sell rating to a hold rating in a report on Wednesday, November 8th. Noble Financial reiterated a buy rating and issued a $24.00 target price on shares of Heron Therapeutics in a report on Friday, October 6th. BidaskClub upgraded Heron Therapeutics from a sell rating to a hold rating in a report on Saturday, August 26th. Cowen set a $40.00 price objective on Heron Therapeutics and gave the stock a buy rating in a report on Thursday, August 3rd. Finally, Aegis restated a buy rating and issued a $33.00 price objective on shares of Heron Therapeutics in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of Buy and an average target price of $28.73.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.15 during midday trading on Friday, reaching $16.95. 699,700 shares of the company’s stock were exchanged, compared to its average volume of 817,792. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $17.98. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. The company had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. equities research analysts forecast that Heron Therapeutics will post -3.42 EPS for the current year.

A number of hedge funds have recently modified their holdings of the stock. Parametric Portfolio Associates LLC lifted its position in Heron Therapeutics by 2.3% in the second quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 771 shares during the period. Schwab Charles Investment Management Inc. lifted its position in Heron Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after purchasing an additional 1,026 shares during the period. Legal & General Group Plc lifted its position in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,098 shares during the period. HighTower Advisors LLC lifted its position in Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 1,700 shares during the period. Finally, Tudor Investment Corp ET AL raised its stake in Heron Therapeutics by 10.2% during the second quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after acquiring an additional 1,724 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Heron Therapeutics (HRTX) Receives Buy Rating from Oppenheimer” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://baseballnewssource.com/markets/heron-therapeutics-hrtx-buy-rating-reaffirmed-at-oppenheimer-holdings-inc/1775624.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot


Leave a Reply

 
© 2006-2017 BBNS.